With the rapid advancement of medical science, the academic concepts and clinical practices in the field of chronic kidney disease (CKD) are undergoing profound changes.  To comprehensively enhance the understanding and management of CKD among nephrologists in China, gain insights into global treatment trends, and explore optimal treatment pathways based on China's national conditions, the "Expert Symposium on Renal Anemia Diagnosis and Treatment" organized by the Chengdu High-Tech Medical Association, was successfully held online on October 20,2025.  This event aims to establish a high-level academic exchange platform, promote clinical practice innovation, and delve into the latest academic hotspots and precision treatment strategies for renal anemia, ultimately benefiting a wide range of CKD patients. Chronic kidney disease is a major public health issue that severely endangers human health, and renal anemia, as one of its most common and critical complications, directly affects patients'quality of life, cardiovascular health, and long-term prognosis.

     In recent years, breakthroughs have been made in the pathogenesis of renal anemia, novel therapeutic targets, and personalized treatment strategies both domestically and internationally.  How to promptly translate these cutting-edge insights into effective clinical practice, and how to develop tailored precision treatment plans that consider the unique disease characteristics and medical resource availability of Chinese patients, have become core issues urgently needing resolution in the field of nephrology.  Against this backdrop, the"Expert Symposium on Diagnosis and Treatment of Renal Anemia"has gathered top domestic experts in nephrology, hematology, and pharmacology. Through various formats such as keynote presentations, hot topic debates, and case discussions, the symposium focuses on the following key areas: In-depth interpretation of the latest guidelines and consensus from both domestic and international sources, comparative analysis of treatment status and differences between CKD and renal anemia in China and abroad, and exploration of optimal solutions tailored to the current diagnostic and therapeutic landscape in China.  Sharing of the latest basic and clinical research achievements in the field of renal anemia, including novel drug mechanisms, new strategies for iron metabolism management, and in-depth clinical applications and experience summaries of HIF-PHI drugs.  In-depth discussions on achieving personalized and precision treatment of renal anemia, covering critical issues such as the fine-tuning of treatment goals, selection of treatment regimens for different populations, and the balance between efficacy and safety.  Combined with real-world cases, exchange diagnosis and treatment experience, analyze the challenges and countermeasures in clinical practice, aiming to unify understanding, standardize behavior, and effectively improve the overall diagnosis and treatment level of renal anemia.       This seminar is not only about imparting knowledge, but also about stimulating thinking and building consensus.  We hope to pool the wisdom of peers across the country to jointly advance the diagnosis and treatment of China's renal anemia, ensuring that every CKD patient can access the most cutting-edge, precise, and humane medical services.  This conference is expected to become a significant academic event in the field of nephrology in China in 2025. Its successful hosting will undoubtedly inject new momentum into the precise diagnosis and treatment of renal anemia in China, provide guidance for optimizing clinical practice, and ultimately make positive contributions to improving the long-term quality of life for China's CKD patients.